«

»

Systemic corticosteroid monotherapy for clinically diagnosed acute rhinosinusitis: a randomized controlled trial

by jmiller on October 25, 2012

In analysis of 94% of the randomized patients, there were no significant differences in symptom outcomes In the prednisolone group, 62.5% had complete resolution of facial pain or pressure at 7 days compared to 55.8% in the placebo group. The median duration of facial pain was 4.5 days with prednisolone vs. 5 days with placebo. The rates of total symptom resolution at 7 days were 32.9% with prednisolone vs. 25.3% with placebo. There were no significant differences in health related quality of life or adverse events at 7 or 14 days or in symptoms in long-term follow-up at 8 weeks. The trial was powered to detect a 20% difference in the rates of pain resolution at 7 days, but the observed difference was only 6.7%, and the trial was underpowered to establish this degree of difference as statistically significant.  Click here for full-text. (CMAJ, Oct)